The University of Chicago Header Logo

Connection

Olufunmilayo Olopade to Receptor, IGF Type 1

Back to Details
This is a "connection" page, showing publications Olufunmilayo Olopade has written about Receptor, IGF Type 1.
Olufunmilayo Olopade
Connection Strength
0.027
Receptor, IGF Type 1
  1. A phase I trial of the IGF-1R antibody Cixutumumab in combination with temsirolimus in patients with metastatic breast cancer. Breast Cancer Res Treat. 2013 May; 139(1):145-53.
    View in: PubMed
    Score: 0.027
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.